| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/13/2000 | CA2358570A1 Protonated/acidified nucleic acids and methods of use |
| 07/13/2000 | CA2358543A1 Human desaturase gene and uses thereof |
| 07/13/2000 | CA2358491A1 Antitumor agents |
| 07/13/2000 | CA2358445A1 Composition and method for enhancing male fertility and libido |
| 07/13/2000 | CA2358438A1 Antiviral method using mek inhibitors |
| 07/13/2000 | CA2358430A1 Potentiation of anti-cd38-immunotoxin cytotoxicity |
| 07/13/2000 | CA2358426A1 Methods and compositions for topical treatment of damaged tissue using reactive oxygen metabolite production or release inhibitors |
| 07/13/2000 | CA2358296A1 Targeted transscleral controlled release drug delivery to the retina and choroid |
| 07/13/2000 | CA2358241A1 Converting cox inhibition compounds that are not cox-2 selective inhibitors to derivatives that are cox-2 selective inhibitors |
| 07/13/2000 | CA2358212A1 Formulations for treating disease and methods of using same |
| 07/13/2000 | CA2358119A1 Compositions and methods relating to cyclic compounds that undergo nucleotide base pair-specific interactions with double-stranded nucleic acids |
| 07/13/2000 | CA2358118A1 Process for producing long chain n-acyl acidic amino acid |
| 07/13/2000 | CA2357986A1 Acid stable backbone modified end-blocked nucleic acids and therapeutic uses thereof |
| 07/13/2000 | CA2357950A1 Therapeutic phosphodiesterase inhibitors |
| 07/13/2000 | CA2357874A1 Cyclic compound |
| 07/13/2000 | CA2357771A1 Imidazo[4,5-c]-pyridine-4-one derivatives |
| 07/13/2000 | CA2356966A1 Amidomalonamides and their use as inhibitors of matrix metalloproteinase |
| 07/13/2000 | CA2356447A1 Use of adenosine agonists in cancer therapy |
| 07/13/2000 | CA2356368A1 Composition and formulations and their use as nociceptic, anti-anxiolytic and anabolic agents |
| 07/13/2000 | CA2356053A1 Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors for the treatment of respiratory diseases |
| 07/13/2000 | CA2355967A1 Astrocytes, their preparation and uses thereof |
| 07/13/2000 | CA2355859A1 Gene therapy-1 |
| 07/13/2000 | CA2355829A1 Multiparticulate oral dosage forms |
| 07/13/2000 | CA2355361A1 New 1,4-disubstituted cyclohexane derivatives for the treatment of depression |
| 07/13/2000 | CA2355342A1 Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression |
| 07/13/2000 | CA2355308A1 3,4-dihydro-2h-benzo¬1,4|oxazinyl-methyl¬3-(1h-indol-3-yl)-alkyl|-amines |
| 07/13/2000 | CA2355302A1 Colchinol derivatives as vascular damaging agents |
| 07/13/2000 | CA2354638A1 Expression of secreted human alpha-fetoprotein in transgenic animals |
| 07/13/2000 | CA2353636A1 Quinolinecarboxamides as antiviral agents |
| 07/13/2000 | CA2353634A1 4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents |
| 07/13/2000 | CA2353592A1 Method and composition for treatment of female sexual dysfunction |
| 07/13/2000 | CA2350946A1 Method of treating sexual disturbances |
| 07/13/2000 | CA2350234A1 Treatment of asthma with mek inhibitors |
| 07/12/2000 | EP1018556A1 Chimeric and/or growth-restricted flaviviruses |
| 07/12/2000 | EP1018513A2 Quinolinecarboxylic acid derivatives |
| 07/12/2000 | EP1018512A1 Novel basic derivatives of benz(e)isoindol-1-ones and pyrrolo(3,4-c)quinolin-1-ones with 5-HT3-antagonistic activity, their preparation and their therapeutic use |
| 07/12/2000 | EP1018511A1 Isochroman compounds and their production process |
| 07/12/2000 | EP1018506A1 Substituted alkyltetramine derivatives |
| 07/12/2000 | EP1018363A1 Nanoemulsion based on sequenced copolymers of ethylene oxyde and propylene oxyde and uses thereof in the fields of cosmetics, dermatology and/or ophthalmology |
| 07/12/2000 | EP1018339A1 Therapeutic agent for intractable vasculitis |
| 07/12/2000 | EP1018338A1 Use of a retinoid type compound to modulate in vivo the decoupling activity of the protein ucp2 |
| 07/12/2000 | EP1018337A2 Formulations containing chlorhexidine, novel chlorhexidine salts,solutions containing the aforesaid chlorhexidine salts and their use |
| 07/12/2000 | EP1018336A1 Carcinostatics |
| 07/12/2000 | EP1018008A2 Method of identification of leads or active compounds |
| 07/12/2000 | EP1017980A2 Methods of the identification of pharmaceutically active compounds |
| 07/12/2000 | EP1017846A1 Control of immune responses by modulating activity of glycosyltransferases |
| 07/12/2000 | EP1017835A1 Methods of using cytochrome p450 reductase for the enhancement of p450-based anti-cancer gene therapy |
| 07/12/2000 | EP1017823A2 Engineered protein kinases which can utilize modified nucleotide triphosphate substrates |
| 07/12/2000 | EP1017807A1 Osf2/cbfa1 compositions and methods of use |
| 07/12/2000 | EP1017801A2 Composition and method for enhancing paracellular transport across cell layers |
| 07/12/2000 | EP1017800A1 Antisense oligonucleotides against thymidylate synthase |
| 07/12/2000 | EP1017790A1 Methods and compositions for binding hematopoietic stem cells |
| 07/12/2000 | EP1017722A2 Compounds with anti-ks and anti-hiv activity |
| 07/12/2000 | EP1017706A1 Cyclic phosphites and phosphates |
| 07/12/2000 | EP1017697A1 MODULES OF PROTEIN TYROSINE PHOSPHATASES (PTPases) |
| 07/12/2000 | EP1017696A1 Acidic addition salts of morphine alkaloids and the application thereof |
| 07/12/2000 | EP1017694A2 N-5,6,7,8-tetrahydro(1,6)naphthyridine-n'-phenylurea derivatives |
| 07/12/2000 | EP1017693A1 Carboxamidothiazole derivatives, preparation, pharmaceutical compositions containing them |
| 07/12/2000 | EP1017692A1 4-heteroaryl-tetrahydroquinolines and their use as inhibitors of the cholesterin-ester transfer protein |
| 07/12/2000 | EP1017691A1 Bisethers of 1-oxa, aza and thianaphthalen-2-ones as phospholamban inhibitors |
| 07/12/2000 | EP1017685A1 New 2-(3h)-oxazolone derivatives |
| 07/12/2000 | EP1017682A1 Novel angiogenesis inhibitors |
| 07/12/2000 | EP1017681A1 Hydrazono-benzazulene derivatives, pharmaceutical compositions and intermediates |
| 07/12/2000 | EP1017680A1 Tricyclic compounds, preparation method and said method intermediates, application as medicines and pharmaceutical compositions containing same |
| 07/12/2000 | EP1017678A1 1,5-diphenylpyrazole derivatives |
| 07/12/2000 | EP1017677A1 4-phenyltetrahydrochinoline utilized as an inhibitor of the cholesterol ester transfer protein |
| 07/12/2000 | EP1017676A1 Method for the synthesis of quinoline derivatives |
| 07/12/2000 | EP1017675A1 Highly lipophilic camptothecin derivatives |
| 07/12/2000 | EP1017673A1 Specific immunophilin ligands useful as anti-asthmatic, anti-allergic, anti-rheumatic, immunosuppressive, antipsoriatic and neuroprotective agents |
| 07/12/2000 | EP1017672A1 New npy antagonists |
| 07/12/2000 | EP1017667A1 2-aminotetralines, a process for their preparation, and pharmaceutical compositions, for the prevention and therapeutic treatment of inflammatory and/or autoimmune pathologies |
| 07/12/2000 | EP1017664A1 C3a receptor ligands |
| 07/12/2000 | EP1017658A1 Benzyl-biphenyls and analogous compounds and the application thereof in order to treat arteriosclerosis and dyslipidaemia |
| 07/12/2000 | EP1017418A1 Vaccine composition for preventing or treating c hepatitis |
| 07/12/2000 | EP1017415A1 Product for promoting dural or meningeal tissue growth comprising collagen |
| 07/12/2000 | EP1017414A1 Therapeutic method for management of diabetes mellitus |
| 07/12/2000 | EP1017408A1 Use of gastrointestinal lipase inhibitors |
| 07/12/2000 | EP1017406A1 Bovine excretion extracts having anticancer and anti-inflammatory activity and process for preparing the same |
| 07/12/2000 | EP1017404A1 Pharmaceutical composition for the treatment of inflammatory bowel disease |
| 07/12/2000 | EP1017403A1 Use of zinc hyaluronate against peptic ulcer |
| 07/12/2000 | EP1017401A2 Treatment and prevention of immunodeficiency virus infection by administration of non-pyrogenic derivatives of lipid a |
| 07/12/2000 | EP1017399A1 Camptothecin analogs and methods of preparation thereof |
| 07/12/2000 | EP1017398A1 Proteasome inhibitors, ubiquitin pathway inhibitors or agents that interfere with the activation of nf-kb via the ubiquitin proteasome pathway to treat inflammatory and autoimmune diseases |
| 07/12/2000 | EP1017397A1 Photosensitizer conjugates for pathogen targeting |
| 07/12/2000 | EP1017396A2 Inhibition of psychostimulant-induced and nicotine-induced craving |
| 07/12/2000 | EP1017395A1 Method for treating premenstrual or late luteal phase syndrome |
| 07/12/2000 | EP1017394A1 Cyclin dependent kinase inhibiting purine derivatives |
| 07/12/2000 | EP1017393A1 Pyrazinone thrombin inhibitors |
| 07/12/2000 | EP1017392A1 Medicament formulation with a controlled release of an active agent |
| 07/12/2000 | EP1017391A2 Sustained release tablet formulation to treat parkinson disease |
| 07/12/2000 | EP1017390A2 Combinations of hmg-coa inhibitors and nicotinic acid compounds and methods for treating hyperlipidemia once a day at night |
| 07/12/2000 | EP1017389A1 Prevention of adhesions and excessive scar formation using angiogenesis inhibitors |
| 07/12/2000 | EP1017388A1 Pharmaceutical compositions containing ibuprofen and domperidone for the treatment of migraine |
| 07/12/2000 | EP1017387A1 Vitronectin receptor antagonist |
| 07/12/2000 | EP1017386A1 GRANULAR PREPARATIONS OF 5-(2-ETHYL- 2$i(H)-TETRAZOL- 5-YL)-1-METHYL-1, 2,3,6-TETRAHYDROPYRIDINE |
| 07/12/2000 | EP1017385A1 USE OF 4-SUBSTITUTED TETRAHYDROPYRIDINES FOR MAKING MEDICINES ACTING ON TGF-beta 1 |
| 07/12/2000 | EP1017384A1 Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function |
| 07/12/2000 | EP1017383A1 Thrombin inhibitors |
| 07/12/2000 | EP1017382A1 Biarylalkanoic acids as cell adhesion inhibitors |
| 07/12/2000 | EP1017381A1 Butyrate derivatives in the treatment of fibromyalgia and chronic fatigue syndrome |